electroCore, Inc.
electroCore, Inc. (ECOR) Stock News
The latest ECOR headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
INNSUITES FY 2027 Q1 RECORDS CONSOLIDATED NET INCOME PROFIT; REVERSE MERGER EXPLORATION CONTINUES
InnSuites Hospitality Trust (IHT) reported Fiscal Q1 2027 net income of $74,702, a $35,672 improvement year-over-year, with record hotel revenue of $2.2 million and combined occupancy reaching 85.37%. The company continues exploring diversification opportunities including a potential reverse merger, IBC Hotels independent hotel services, and investments in UniGen Power's clean energy technology.
- Benzinga·
DR. PHONE FIX REPORTS RECORD Q1 2026 RESULTS AND CONTINUED NATIONAL EXPANSION MOMENTUM
Q1 Revenue Up 44% YoY; Same-Store Sales Up 29%; Adjusted EBITDA Turns Positive as Company Advances National Expansion Strategy EDMONTON, AB , June 1, 2026 /CNW/ - Dr. Phone Fix Canada Corporation (TSXV: DPF) ("Dr. Phone Fix" or the "Company"), one of Canada's fastest-growing and award-winning consumer electronics repair and resale platforms, today reported financial results for the three months ended March 31, 2026, and provided an update on recent corporate developments. The Company operates a network of 44 corporately owned stores across five Canadian provinces. Financial Results Summary (CAD) (all dollar amounts in 000's) Three Months Ended Mar 31, 2026 Three Months Ended Mar 31, 2025 Variance (%) Revenue 3,162 2,196 +44 % Gross Profit 1,621 1,210 +34 % Gross Margin 51.3 % 55.1 % -3.8 pp Operating Expenses (SG&A) 2,476 1,754 +41 % Adjusted EBITDA(1) 88 (13) n/m Cash 291 1,558 -81 % (1) See Non-GAAP Financial Measure towards the end of this document. "Q1 reflected continued progress in the execution of our strategy with revenue increasing 44% year-over-year and comparable-store sales increasing 29%, even in what is typically our seasonally weakest quarter," said Piyush Sawhney, Founder and Chief Executive Officer of Dr. Phone Fix. "We also delivered positive Adjusted EBITDA, generated positive operating cash flow, and continued to improve execution across our national network while integrating recently acquired locations and advancing our OEM, insurance, supplier, repair and certified pre-owned device programs." Mr. Sawhney continued, "We have spent the past year building the foundation for a national, carrier-neutral device lifecycle platform. Today, we have 44 corporately owned locations across five provinces, a growing pipeline of acquisition and greenfield opportunities, and a strategy focused on disciplined expansion and stronger unit-level economics throug
- Benzinga·
LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS
LSL Pharma Group Reports Record Q1-2026 Revenues while positioning for improved profitability following Steri-Med Pharma production resumption. Launch of new eye-drop portfolio planned for the second quarter of 2026. Secured US-FDA certification of Steri-Med to manufacture ophthalmic ointment for the US market. BOUCHERVILLE, QC , May 25, 2026 /CNW/ - LSL PHARMA GROUP INC . (TSXV: LSL ) (the " Corporation " or " LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2026 ("Q1-26"). All amounts are presented in millions ("M") of Canadian dollars. Q1-26 Corporate and Financial Highlights Record quarterly consolidated revenues, including full quarter contribution from Laboratoire Du-Var ("Du-Var") and Juno OTC acquired on January 1 st , 2026 and to be presented as 3 rd business segment; Strong Eye-Care revenues show significant market share gains in Canada; Q1-26 profitability temporarily impacted by the three-month Steri-Med Pharma (Steri-Med) production pause, with full production activities having resumed in April 2026; Secured US-FDA certification of Steri-Med to manufacture ophthalmic ointment for the US market; Commissioning of new state-of-the-art sterile ointment manufacturing line on track for commercial production by Q1-27; Development of three (3) new ointment products initiated for regulatory filings during FY-27. Binding term sheet signed with Instapill Private Limited ("Instapill") for the Canadian rights to private label Loratadine 10 mg Orally Disintegrating Tablets (ODT), a bioequivalent product to Claritin® Rapid Dissolve TM ; Revolving credit facility increased from $7.5M to $11M; "During the first quarter of 2026, we saw the positive impact of the recent acquisitions of Juno OTC and Du-Var on our operating results and the diversification of our business platform. Whil
- Benzinga·
TURPAZ INDUSTRIES LTD. ANNOUNCES RECORD FIRST QUARTER 2026 RESULTS
English Conference Call Scheduled at 10am Eastern Time and 5pm Israel Time CAESAREA, Israel , May 18, 2026 /PRNewswire/ -- Turpaz Industries Ltd. (TASE: TRPZ), a global company that develops and manufactures thousands of flavor and fragrance extracts, intermediates and specialty fine ingredients and markets and sells them in more than 95 countries around the world, today announced its financial results for the first quarter ended March 31, 2026, demonstrating continued double-digit growth across all key financial metrics and a significant acceleration in its global expansion. Q1 2026 Financial Highlights Revenues grew 38.6% to a record $83.6 million, with organic growth of approximately 9%; Adjusted EBITDA increased 42.4% to $19.4 million, representing 23.2% of revenues; Net income more than doubled, growing 104.5% to $11.1 million; Non-GAAP net income grew by 48.8% to $11.7 million. Current revenue run-rate (as of reporting date) of approximately $380 million following the recent acquisitions in the U.S. and France. Management Comment Karen Cohen Khazon, Chief Executive Officer of Turpaz Industries, said, "We started 2026 with continued strong growth and record results, reflecting the strength of Turpaz's growth strategy and our execution capabilities. The combination of strong organic growth together with synergistic acquisitions continues to prove itself as a significant growth engine." "The recent acquisitions we completed in the U.S. and France represent an important strategic step in expanding our global footprint, strengthening our presence in key markets and segments with high growth potential, primarily fine fragrances and North America." "The Group's financial strength, together with cooperation with leading global banks and financial institutions, combined with the extensive experience of Turpaz's management team and its dedicated employees, enables us to c